| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Guangzhou LBP Medicine Science & Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥16.46 |
| 52 Week High | CN¥34.48 |
| 52 Week Low | CN¥12.83 |
| Beta | 0.45 |
| 1 Month Change | -17.99% |
| 3 Month Change | -27.20% |
| 1 Year Change | -38.97% |
| 3 Year Change | -54.53% |
| 5 Year Change | n/a |
| Change since IPO | -72.78% |
Recent News & Updates
Shareholder Returns
| 688393 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | -8.6% | -2.4% | -0.2% |
| 1Y | -39.0% | -23.1% | -17.8% |
Return vs Industry: 688393 underperformed the CN Medical Equipment industry which returned -25% over the past year.
Return vs Market: 688393 underperformed the CN Market which returned -21.1% over the past year.
Price Volatility
| 688393 volatility | |
|---|---|
| 688393 Average Weekly Movement | 11.9% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 688393's share price has been volatile over the past 3 months.
Volatility Over Time: 688393's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 829 | Xiangting Cai | www.gzlbp.com |
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China. The company offers pathological diagnostic reagents and ancillary equipment that consists of liquid-based cytology products, including liquid-based cytology production machines and automatic sample transfer machines; polymerase chain reaction products, such as human papillomavirus gene test kits, sample preservation solutions, and automatic nucleic acid molecular hybridization instruments; fluorescence in situ hybridization products comprising auto-fish instruments, and AML1/ETO, EGFR, BCR/ABL fusion, PML/RARA, and TOP2A gene testing kits; and digital pathology products pathological medical image analysis processing systems, real-time microscopic visual field sharing systems, and bingli scanner.
Guangzhou LBP Medicine Science & Technology Co., Ltd. Fundamentals Summary
| 688393 fundamental statistics | |
|---|---|
| Market cap | CN¥1.54b |
| Earnings (TTM) | CN¥40.30m |
| Revenue (TTM) | CN¥497.29m |
38.2x
P/E Ratio3.1x
P/S RatioIs 688393 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688393 income statement (TTM) | |
|---|---|
| Revenue | CN¥497.29m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥497.29m |
| Other Expenses | CN¥456.99m |
| Earnings | CN¥40.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 23, 2024
| Earnings per share (EPS) | 0.43 |
| Gross Margin | 100.00% |
| Net Profit Margin | 8.10% |
| Debt/Equity Ratio | 1.7% |
How did 688393 perform over the long term?
See historical performance and comparison